Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55

1.

Descriptors for High Throughput in Structural Materials Development.

Steinbacher M, Alexe G, Baune M, Bobrov I, Bösing I, Clausen B, Czotscher T, Epp J, Fischer A, Langstädtler L, Meyer D, Raj Menon S, Riemer O, Sonnenberg H, Thomann A, Toenjes A, Vollertsen F, Wielki N, Ellendt N.

High Throughput. 2019 Dec 5;8(4). pii: E22. doi: 10.3390/ht8040022.

2.

Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.

Cremer A, Ellegast JM, Alexe G, Frank ES, Ross L, Chu SH, Pikman Y, Robichaud A, Goodale A, Häupl B, Mohr S, Rao AV, Walker AR, Blachly JS, Piccioni F, Armstrong SA, Byrd JC, Oellerich T, Stegmaier K.

Cancer Discov. 2020 Feb;10(2):214-231. doi: 10.1158/2159-8290.CD-19-0209. Epub 2019 Nov 26.

PMID:
31771968
3.

Single-cell cloning of human T-cell lines reveals clonal variation in cell death responses to chemotherapeutics.

Hanlon K, Thompson A, Pantano L, Hutchinson JN, Al-Obeidi A, Wang S, Bliss-Moreau M, Helble J, Alexe G, Stegmaier K, Bauer DE, Croker BA.

Cancer Genet. 2019 Sep;237:69-77. doi: 10.1016/j.cancergen.2019.06.003. Epub 2019 Jun 12.

PMID:
31447068
4.

Therapeutic discovery for marrow failure with MDS predisposition using pluripotent stem cells.

Ruiz-Gutierrez M, Bölükbaşı ÖV, Alexe G, Kotini AG, Ballotti K, Joyce CE, Russell DW, Stegmaier K, Myers K, Novina CD, Papapetrou EP, Shimamura A.

JCI Insight. 2019 Apr 30;5. pii: 125157. doi: 10.1172/jci.insight.125157.

5.

High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma.

Wang S, Hwang EE, Guha R, O'Neill AF, Melong N, Veinotte CJ, Conway Saur A, Wuerthele K, Shen M, McKnight C, Alexe G, Lemieux ME, Wang A, Hughes E, Xu X, Boxer MB, Hall MD, Kung A, Berman JN, Davis MI, Stegmaier K, Crompton BD.

Clin Cancer Res. 2019 Jul 15;25(14):4552-4566. doi: 10.1158/1078-0432.CCR-17-0375. Epub 2019 Apr 12.

PMID:
30979745
6.

Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling.

Iniguez AB, Alexe G, Wang EJ, Roti G, Patel S, Chen L, Kitara S, Conway A, Robichaud AL, Stolte B, Bandopadhayay P, Goodale A, Pantel S, Lee Y, Cheff DM, Hall MD, Guha R, Davis MI, Menard M, Nasholm N, Weiss WA, Qi J, Beroukhim R, Piccioni F, Johannessen C, Stegmaier K.

Cancer Cell. 2018 Dec 10;34(6):922-938.e7. doi: 10.1016/j.ccell.2018.11.005.

7.

The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy.

Liu S, Marneth AE, Alexe G, Walker SR, Gandler HI, Ye DQ, Labella K, Mathur R, Toniolo PA, Tillgren M, Gokhale PC, Barbie D, Mullally A, Stegmaier K, Frank DA.

Blood Adv. 2018 Dec 11;2(23):3428-3442. doi: 10.1182/bloodadvances.2018016733.

8.

A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.

Guenther LM, Dharia NV, Ross L, Conway A, Robichaud AL, Catlett JL 2nd, Wechsler CS, Frank ES, Goodale A, Church AJ, Tseng YY, Guha R, McKnight CG, Janeway KA, Boehm JS, Mora J, Davis MI, Alexe G, Piccioni F, Stegmaier K.

Clin Cancer Res. 2019 Feb 15;25(4):1343-1357. doi: 10.1158/1078-0432.CCR-18-0372. Epub 2018 Nov 5.

9.

Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML.

Benajiba L, Alexe G, Su A, Raffoux E, Soulier J, Hemann MT, Hermine O, Itzykson R, Stegmaier K, Puissant A.

Leukemia. 2019 Mar;33(3):800-804. doi: 10.1038/s41375-018-0291-x. Epub 2018 Nov 2. No abstract available.

10.

Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma.

Stolte B, Iniguez AB, Dharia NV, Robichaud AL, Conway AS, Morgan AM, Alexe G, Schauer NJ, Liu X, Bird GH, Tsherniak A, Vazquez F, Buhrlage SJ, Walensky LD, Stegmaier K.

J Exp Med. 2018 Aug 6;215(8):2137-2155. doi: 10.1084/jem.20171066. Epub 2018 Jul 25.

11.

KLF5 controls glutathione metabolism to suppress p190-BCR-ABL+ B-cell lymphoblastic leukemia.

Zhang C, D'Alessandro A, Wellendorf AM, Mohmoud F, Serrano-Lopez J, Perentesis JP, Komurov K, Alexe G, Stegmaier K, Whitsett JA, Grimes HL, Cancelas JA.

Oncotarget. 2018 Jul 3;9(51):29665-29679. doi: 10.18632/oncotarget.25667. eCollection 2018 Jul 3.

12.

Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia.

Wagner FF, Benajiba L, Campbell AJ, Weïwer M, Sacher JR, Gale JP, Ross L, Puissant A, Alexe G, Conway A, Back M, Pikman Y, Galinsky I, DeAngelo DJ, Stone RM, Kaya T, Shi X, Robers MB, Machleidt T, Wilkinson J, Hermine O, Kung A, Stein AJ, Lakshminarasimhan D, Hemann MT, Scolnick E, Zhang YL, Pan JQ, Stegmaier K, Holson EB.

Sci Transl Med. 2018 Mar 7;10(431). pii: eaam8460. doi: 10.1126/scitranslmed.aam8460.

13.

Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia.

Baldoni S, Del Papa B, Dorillo E, Aureli P, De Falco F, Rompietti C, Sorcini D, Varasano E, Cecchini D, Zei T, Di Tommaso A, Rosati E, Alexe G, Roti G, Stegmaier K, Di Ianni M, Falzetti F, Sportoletti P.

Int J Cancer. 2018 Aug 15;143(4):958-970. doi: 10.1002/ijc.31355. Epub 2018 Mar 23.

14.

EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma.

Iniguez AB, Stolte B, Wang EJ, Conway AS, Alexe G, Dharia NV, Kwiatkowski N, Zhang T, Abraham BJ, Mora J, Kalev P, Leggett A, Chowdhury D, Benes CH, Young RA, Gray NS, Stegmaier K.

Cancer Cell. 2018 Feb 12;33(2):202-216.e6. doi: 10.1016/j.ccell.2017.12.009. Epub 2018 Jan 18.

15.

Model-assisted measuring method for periodical sub-wavelength nanostructures.

Alexe G, Tausendfreund A, Stöbener D, Fischer A.

Appl Opt. 2018 Jan 1;57(1):92-101. doi: 10.1364/AO.57.000092.

PMID:
29328122
16.

Origin and differentiation of human memory CD8 T cells after vaccination.

Akondy RS, Fitch M, Edupuganti S, Yang S, Kissick HT, Li KW, Youngblood BA, Abdelsamed HA, McGuire DJ, Cohen KW, Alexe G, Nagar S, McCausland MM, Gupta S, Tata P, Haining WN, McElrath MJ, Zhang D, Hu B, Greenleaf WJ, Goronzy JJ, Mulligan MJ, Hellerstein M, Ahmed R.

Nature. 2017 Dec 21;552(7685):362-367. doi: 10.1038/nature24633. Epub 2017 Dec 13.

17.

CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.

Chen L, Alexe G, Dharia NV, Ross L, Iniguez AB, Conway AS, Wang EJ, Veschi V, Lam N, Qi J, Gustafson WC, Nasholm N, Vazquez F, Weir BA, Cowley GS, Ali LD, Pantel S, Jiang G, Harrington WF, Lee Y, Goodale A, Lubonja R, Krill-Burger JM, Meyers RM, Tsherniak A, Root DE, Bradner JE, Golub TR, Roberts CW, Hahn WC, Weiss WA, Thiele CJ, Stegmaier K.

J Clin Invest. 2018 Jan 2;128(1):446-462. doi: 10.1172/JCI90793. Epub 2017 Dec 4.

18.

TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia.

Lobbardi R, Pinder J, Martinez-Pastor B, Theodorou M, Blackburn JS, Abraham BJ, Namiki Y, Mansour M, Abdelfattah NS, Molodtsov A, Alexe G, Toiber D, de Waard M, Jain E, Boukhali M, Lion M, Bhere D, Shah K, Gutierrez A, Stegmaier K, Silverman LB, Sadreyev RI, Asara JM, Oettinger MA, Haas W, Look AT, Young RA, Mostoslavsky R, Dellaire G, Langenau DM.

Cancer Discov. 2017 Nov;7(11):1336-1353. doi: 10.1158/2159-8290.CD-17-0267. Epub 2017 Oct 3.

19.

Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia.

Mohr S, Doebele C, Comoglio F, Berg T, Beck J, Bohnenberger H, Alexe G, Corso J, Ströbel P, Wachter A, Beissbarth T, Schnütgen F, Cremer A, Haetscher N, Göllner S, Rouhi A, Palmqvist L, Rieger MA, Schroeder T, Bönig H, Müller-Tidow C, Kuchenbauer F, Schütz E, Green AR, Urlaub H, Stegmaier K, Humphries RK, Serve H, Oellerich T.

Cancer Cell. 2017 Apr 10;31(4):549-562.e11. doi: 10.1016/j.ccell.2017.03.001.

20.

The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.

Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Conway AS, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, Zhang Y, Perkins AS, Shannon K, Hemann MT, Puissant A, Stegmaier K.

Nat Med. 2017 Mar;23(3):301-313. doi: 10.1038/nm.4283. Epub 2017 Feb 13.

Supplemental Content

Loading ...
Support Center